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Summary Catamenial epilepsy (CE) is characterized by epileptic seizures in the
female occurring rhythmatically with the menstrual cycle. Hormonal mechanisms
have been proposed as a cause of this epileptic form. Few reports about the efficacy of
anti-epileptic drugs (AEDs) have been published. We studied prospectively women
with CE who were treated with lamotrigine (LTG) for a period of 3 months in order to
evaluate its efficacy, measuring the progesterone levels before and after LTG at the
same time. LTG seemed to be efficacious in 66% of women, meaning the disappear-
ance of seizures or reduction of 50% or more of the number of seizures. The reported
side effects were few and mild, and the drug was well tolerated. Serum progesterone
levels were found to rise during LTG treatment.
# 2008 Published by Elsevier Ltd on behalf of British Epilepsy Association.Introduction
Catamenial epilepsy (CE) is defined as the occur-
rence of seizures around the time of menses or an
increase in seizures in relation to the menstrual
cycle. According to Duncan et al.,1 the criteria of
having at least 75% of the seizures over the 10 days
beginning 4 days before menstruation is necessary
to fit this description. Herzog et al.2 defined CE as
a greater than average seizure frequency during
perimenstrual and periovulatory periods in normal
ovulatory cycles and during the luteal phase in* Corresponding author. Tel.: +972 3 502 8512;
fax: +972 3 502 8681.
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to 72% in various studies,1,3 occurring in perhaps a
third ofwomenwith epilepsy. It has been postulated
that there is correlation between the seizure fre-
quency and estradiol to progesterone (E/P) serum
ratio concentration during the menstrual cycle.
Recent studies have shown that cyclic changes of
ovarian hormones — estrogen (proconvulsive) and
progesterone (anti-convulsive) — appear to play a
key role in the pathogenesis of catamenial sei-
zures.4,5 Lamotrigine (LTG) is reported anecdotally
to have an effect on catamenial epilepsy. No reports
of special efficacy on most of the other frequently
used anti-epileptic drugs (AEDs) have been pub-
lished on this particular group. The use of hormonal,
as well as non-hormonal therapy (progesterone and
its derivatives, oral contraceptive (OC), acetazo-
lamide, and conventional AED), has been reportedn behalf of British Epilepsy Association.
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Table 1 Progesterone levels in the study patients with
LTG treatment
Patient no. Before LTG After LTGto have limited efficacy.6—10 We preformed a pro-
spective study for evaluation of the efficacy of


















Mean 9.13  4.96 10.7  4.95
a Patients # 1—# 3 are women with anovulatory cycles.Experimental/materials and methods
All women suffering from catamenial epilepsy
according to the three distinct patterns of CE pro-
posed by Herzog,2 those with newly diagnosed CE
and those patients who had intractable seizures
under a first line anti-epileptic drug were included
in the study. Excluded were patients who were
previously treated with or had allergic reactions
to LTG. The study patients completed a bimonthly
diary which included details of seizure occurrence
and menstruation before starting LTG treatment.
Each of the patients underwent MRI examination, as
well as EEG. In those patients, who had been under
other AED medication and were refractory to their
treatment (at least four attacks in every month for
the last 2 months), the previous treatment was
discontinued and lamotrigine therapy started. In
all patients, lamotrigine, as monotherapy, was
started with 25 mg daily, and the dosage gradually
increased up to 100 mg (b.i.d.). The change of
treatment dosage was done according to our proto-
col for the various AEDs. The progesterone levels
were measured twice before beginning LTG treat-
ment during two consecutive months and 3 months
after initiating LTG treatment as monotherapy. The
progesterone levels were done at day 20—24 in
women with ovulation. In women with anovulatory
cycles, the progesterone level was taken during the
midluteal phase. None of the patients was taking
oral contraceptives. The diagnosis of ovulatory or
non-ovulatory cycles was made in the gynecological
outpatient clinic by using the midluteal phase pro-
gesterone level results. The period of follow-up was
3 months.
All serum samples were tested with the same
‘‘ECLIA’’ immunoassay (Elecsys module-COBAS) for
measurement of the progesterone levels. Its mean
coefficient variation is around 4—5%, having very
small variability in the assay results.Results
Seventy-five women (mean age 31  13.5 years)
were evaluated for inclusion into the study. Eigh-
teen patients (mean age 28  8.7; range 22—38
years), three being anovulatory, fulfilled the cri-
teria of CE. The type of seizures included 2 with
simple-partial seizures, 11 patients with complex-
partial seizures, and 5 with primary generalizedtonic—clonic seizures. The mean number of sei-
zures during the last 2 months was 5  3 (range 4—
9). Their mean progesterone levels before and
during LTG treatment are summarized in Table 1.
In six of the study patients, CE was diagnosed at
puberty, in eight patients between the ages of 18—
25 and in four patients, between the ages of 25—
30. Eleven were refractory to one of the AEDs (five
on valproic acid and six on carbamazepine) and
none of whom being previously treated with LTG,
were switched to the study medication. Five
patients just newly diagnosed with epilepsy began
their treatment with LTG. Two other patients were
switched from other AEDs because of adverse side
effects (one from topiramate due to confusion,
one from phenytoin due to abnormal blood liver
tests).
Among the 18 patients treated with LTG, one
patient’s treatment was discontinued at a dosage
of 200 mg due to a skin rash which disappeared after
discontinuation of therapy. Three women com-
plained of dizziness and headaches which disap-
peared within 10 days of treatment. Serum
progesterone levels increased during the period of
LTG treatment compared to the samples taken during
other AED treatment or when under no treatment at
all. The change of the mean progesterone serum
levels was from 9.13  4.96 to 10.7  4.95 ng/ml
(p = 0.002). In four women (22%), all seizure attacks
disappeared in the follow-up period of 3 months. In a
further eight patients, there was a 50% reduction of
seizures, respective to the two previous months of
Lamotrigine and catamenial epilepsy 533treatment. In six patients, lamotrigine was ineffec-
tive. Therefore, concluding that, in 66% of women
with CE, LTG was effective with no severe adverse
effects, by stopping completely or reducing more
than >50% of seizures. There was no difference
between the newly diagnosedwomen and the refrac-
tory group of women in regards to the treatment
response with LTG.Discussion
According to the present study, lamotrigine had a
beneficial effect of 66% (22% became seizure-free
and 44% had a 50% reduction in number of seizures)
in the CE cases where the use of the standard AEDs
had failed. There are no studies analyzing the
efficacy of AED in CE. This effect by lamotrigine
can be explained by the fact that this medication
is not involved in the dynamic equilibrium changes
between estrogen and progesterone during
menses. Other AEDs have enzyme-inducing activity
and lead to reduced plasma steroid concentration,
except for Valproic acid, which is not enzyme-
inducing. In the case of patients treated with
VPA, another explanation is needed. In our study,
less than a third of the patients were on VPA and
switched to LTG because of side effects or ineffec-
tiveness. This enzyme action affects estrogen and
its metabolites, and in addition, especially acts on
progesterone. Morell defined the relationship
between lamotrigine in woman with epilepsy and
anovulating menstrual cycles as advantageous.11
The newer drugs, gabapentin and lamotrigine, may
have some advantages for women with epilepsy
because they do not alter levels of steroids hor-
mones and interfere less with the effectiveness of
hormonal contraception. Other theories as ratio-
nale for the beneficial effect of lamotrigine on CE
in our findings can be attributed to the serum
progesterone concentration rise which was
observed in our patients having anti-convulsant
properties. Adult animal models of epilepsy and
clinical evidence suggest that estrogen has exci-
tatory and progesterone has inhibitory effects o
neuronal excitability and seizures.2 The protection
of progesterone against seizures in animals is
attributed to the reduced progesterone metabo-
lite tetrahydroprogesterone (THP), also known as
allopregnanolone, a GABAA receptor modulating
neurosteroid with anti-convulsant properties.12
There is also a possibility of the presence of
increased progesterone level production, as a
result of better seizure control. It seems to us
that the described cases suggest the probable
efficacy of lamotrigine in intractable CE and theimportance of understanding its properties for the
treatment of these patients, even though the
exact mechanism of action is unknown. It is known
that AED effectively controls seizures in two-thirds
of the epilepsy population, so the favorable out-
come of LTG treatment in CE was not completely
unexpected. However, a special subpopulation of
epileptic women with good efficacy and tolerabil-
ity with LTG was described. Further expanded
studies with more comprehensive hormonal
screening are needed to confirm these findings
of lamotrigine efficacy in CE as demonstrated in
our presented cases.Conclusions
In our study, using LTG for AED therapy in CE patients
was efficacious; a result which was confirmed in
other studies when it was given either as add-on
or monotherapy. There is a possibility that hormonal
factors, especially those of progesterone, may have
some influence on women with CE; further studies
are needed to investigate this observation.Acknowledgment
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